about
Isolated extramedullary breast relapses in inv(16) positive and c-KIT negative acute myeloid leukemia after allogenic hematopoietic stem cell transplantation - description of two casesCoexistence of chronic lymphocytic leukemia and myeloproliferative neoplasm.Reduced-toxicity conditioning with treosulfan and fludarabine in allogeneic hematopoietic stem cell transplantation for myelodysplastic syndromes: final results of an international prospective phase II trial.Fungal colonization of the respiratory tract in allogeneic and autologous hematopoietic stem cell transplant recipients: a study of 573 transplanted patients.A CT60G>A polymorphism in the CTLA-4 gene of the recipient may confer susceptibility to acute graft versus host disease after allogeneic hematopoietic stem cell transplantationPhenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populationsTreating oral mucositis with a supersaturated calcium phosphate rinse: comparison with control in patients undergoing allogeneic hematopoietic stem cell transplantation.The Presence of Anti-HLA Antibodies before and after Allogeneic Hematopoietic Stem Cells Transplantation from HLA-Mismatched Unrelated Donors.Effects of Transendocardial Delivery of Bone Marrow-Derived CD133+ Cells on Left Ventricle Perfusion and Function in Patients With Refractory Angina: Final Results of Randomized, Double-Blinded, Placebo-Controlled REGENT-VSEL Trial.Allogeneic hematopoietic SCT in patients with AML following treosulfan/fludarabine conditioning.Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.Pretransplant donor and recipient CTLA-4 mRNA and protein levels as a prognostic marker for aGvHD in allogeneic hematopoietic stem cell transplantation.Role of Donor Activating KIR-HLA Ligand-Mediated NK Cell Education Status in Control of Malignancy in Hematopoietic Cell Transplant Recipients.Beneficial effect of the CXCL12-3'A variant for patients undergoing hematopoietic stem cell transplantation from unrelated donors.NOD2/CARD15 single nucleotide polymorphism 13 (3020insC) is associated with risk of sepsis and single nucleotide polymorphism 8 (2104C>T) with herpes viruses reactivation in patients after allogeneic hematopoietic stem cell transplantation.Clinical characteristics of patients with chronic eosinophilic leukaemia (CEL) harbouring FIP1L1-PDGFRA fusion transcript--results of Polish multicentre study.Palifermin does not influence the incidence and severity of GvHD nor long-term survival of patients with hematological diseases undergoing HSCT.Unrelated donor bone marrow transplantation with treosulfan-based myeloablative conditioning for paroxysmal nocturnal hemoglobinuria--successful treatment despite multiple transplant-related risk factors for hemolysis including major Kidd group incoSuccessful treatment of pure red cell aplasia with repeated, low doses of rituximab in two patients after ABO-incompatible allogeneic haematopoietic stem cell transplantation for acute myeloid leukaemia.IL-10 promoter polymorphisms influence susceptibility to aGvHD and are associated with proportions of CD4+FoxP3+ lymphocytes in blood after hematopoietic stem cell transplantation.Safety profile of autologous hematopoietic stem cell mobilization and transplantation in patients with systemic sclerosis.Donor NK cell licensing in control of malignancy in hematopoietic stem cell transplant recipients.Comparision of benefits of early, delayed, and no administration of G-CSF after autologous peripheral blood stem cell transplantation in lymphoma patients.The impact of H-Y mismatches on results of HLA-matched unrelated allogeneic hematopoietic stem cell transplantation.Acute graft-versus-host disease. The incidence and risk factors.Mild chronic graft-versus-host disease may alleviate poor prognosis associated with FLT3 internal tandem duplication for adult acute myeloid leukemia following allogeneic stem cell transplantation with myeloablative conditioning in first complete reThe Influence of Genetic Variations in the CD86 Gene on the Outcome after Allogeneic Hematopoietic Stem Cell Transplantation.Safety and outcome of allogeneic stem cell transplantation in myelofibrosis.Trends in patient outcome over the past two decades following allogeneic stem cell transplantation for acute myeloid leukemia. An ALWP/EBMT analysisInherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patientsSplenic irradiation before allogeneic stem cell transplantation for myelofibrosisStem cell transplantation for congenital dyserythropoietic anemia. An analysis from the European society for blood and marrow transplantationAllogeneic transplantation for high-risk chronic lymphocytic leukemia-a summary of a 16-year experience[Level of erythropoietin during autologous transplantation of stem cells from bone marrow and peripheral blood][Techniques of positive isolation of CD34(+) cells. Personal experience with the immunomagnetic method]Autologous peripheral blood stem and progenitor cells transplantation as a valid treatment approach in recurrent, refractory lymphomaAutologous bone marrow transplantation in adult acute lymphoblastic leukaemiaImmunomagnetic method of CD34(+) cell separation[Excretion of beta-2-microglobulin and Tamm-Horsfall protein in patients undergoing a conditioning regimen before bone marrow transplantation][Autologous peripheral blood stem cell transplantation as an effective treatment for recurrent Hodgkin's disease]
P50
Q33935391-BF046B31-0FDE-4C38-A265-46A133A7E385Q34200436-B765D971-F913-46BD-AF6F-EE6E703D5CFBQ35193735-A0B0464B-26AB-4835-8FD5-716DC63E93A5Q35579273-943491F6-0CE6-4A95-B3E8-E830C40E370DQ35594106-79E32922-0AD0-4CB4-BC9A-5952B9465636Q35865440-B2D1D493-45F9-40A3-86FE-02E59034D7F5Q36138187-DB40DBFA-ED7E-43F8-8173-DF7EF5EDAE5DQ36369256-24C6655A-4034-4000-9218-4001C30D81DCQ38384000-F2AD1873-9304-426C-91EB-387C5D56F83BQ38479720-FFAA1847-901D-4412-86F5-8C167000CC27Q40418824-C15764E4-9C22-414B-8A11-03BCA76CA146Q41116631-45215D98-57FC-4384-A5E3-0E60E90D5E6BQ41532474-9B026FEA-DF12-431C-9304-1832BBABD44CQ41732815-9D41278A-3BDE-4952-BAFC-9786FA516406Q42248606-D2E2355D-54B4-45E2-A42A-F817FED9CAE7Q43281442-390062D9-A6CC-4780-A375-70DADBA71135Q43751721-BBE29045-614D-484E-8BD8-29BE4B10A62EQ46772640-C90EFA6B-AEF5-469E-B2D5-D35777086779Q46788328-D08A0AF7-19B8-4723-B532-8B23DF985F31Q46812391-02A44D88-E8FE-4D34-8342-1E86E96286EDQ47562795-6F518B99-074A-44B0-9576-760A6A7D57F6Q48846219-EF1782DE-DE1A-448E-9568-A8FEDE50F134Q50865088-717761E5-F03E-4CFE-AEB5-D8D3F8BFA8EBQ51536134-AC09B343-92ED-4C6F-8CCE-7D55839CCDECQ51781841-AC0B49BB-3913-40C0-ACD3-257E1B27190DQ54275690-3397A355-D991-40BD-A18B-A740315D697FQ54965204-532980B7-E52B-4FE5-8373-280D1CA85211Q55060741-8F10EBBE-A7EE-4DDB-98A7-192678F1250EQ58104454-675A375A-85B5-4586-BC64-25AB580739C3Q59244985-B9BB2DA0-C143-43AC-B63E-FC5D8CE08E17Q61450346-0DA32F20-F0E4-4E77-BD99-F8A712EBF729Q64117814-115DF55C-D8F2-4FFA-B62B-27895AB5A47EQ64246205-4AB639B6-34C5-4056-BFC3-C40C8F75317CQ70797462-87DF057F-32AC-4505-AD7A-7E71208D904DQ71076255-0ED2DF58-C53E-4D67-B6FB-817B597DF8C5Q71357327-3237AC35-544A-48AE-A65B-E12AD0D4E536Q71879444-3646628F-B3E1-414D-8BDC-396C30D5C278Q71879452-97AA9237-6FE5-4D20-B1A1-2998AF2EE71CQ72620563-DF216DEC-3CD4-4183-B6B5-5FBDCE265304Q74431467-440BF9FE-DFFD-428B-A9F9-C3A17E58B477
P50
description
researcher ORCID ID = 0000-0002-8550-8908
@en
wetenschapper
@nl
name
Miroslaw Markiewicz
@ast
Miroslaw Markiewicz
@en
Miroslaw Markiewicz
@es
Miroslaw Markiewicz
@ga
Miroslaw Markiewicz
@nl
Mirosław Markiewicz
@ca
Mirosław Markiewicz
@cs
Mirosław Markiewicz
@gl
Mirosław Markiewicz
@hr
Mirosław Markiewicz
@hsb
type
label
Miroslaw Markiewicz
@ast
Miroslaw Markiewicz
@en
Miroslaw Markiewicz
@es
Miroslaw Markiewicz
@ga
Miroslaw Markiewicz
@nl
Mirosław Markiewicz
@ca
Mirosław Markiewicz
@cs
Mirosław Markiewicz
@gl
Mirosław Markiewicz
@hr
Mirosław Markiewicz
@hsb
prefLabel
Miroslaw Markiewicz
@ast
Miroslaw Markiewicz
@en
Miroslaw Markiewicz
@es
Miroslaw Markiewicz
@ga
Miroslaw Markiewicz
@nl
Mirosław Markiewicz
@ca
Mirosław Markiewicz
@cs
Mirosław Markiewicz
@gl
Mirosław Markiewicz
@hr
Mirosław Markiewicz
@hsb
P214
P1153
7102243748
P1412
P1559
Mirosław Markiewicz
@pl
P21
P214
P27
P31
P496
0000-0002-8550-8908
P734
P735
P7859
viaf-162516373